Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: The HPMPC peripheral cytomegalovirus retinitis trial. The studies of ocular complications of AIDS research group in collaboration with the AIDS clinical trials group

AIDS

Volumn 14, Issue 11, 2000, Pages 1571-1581

  Jabs, D A ^a   Freeman, W R ^a   Jacobson, M ^a   Murphy, R ^a   Van Natta, M L ^a   Meinert, C L ^a  

^a NONE   (United States)

Author keywords

AIDS; Cidofovir; Cytomegalovirus retinitis; Nephrotoxicity; Uveitis

Indexed keywords

CIDOFOVIR; PROBENECID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISEASE COURSE; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; OPHTHALMOSCOPY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RETINITIS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS RETINITIS; CYTOSINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MORBIDITY; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; TIME FACTORS; TREATMENT OUTCOME; VISION;

EID: 0033816267     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200007280-00013     Document Type: Article

References (46)

1. Cytomegalovirus retinitis and acquired immunodeficiency syndrome
2. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine
3. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus
4. Ocular manifestations of HIV infection
5. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression
6. Natural history of opportunistic disease in an HIV-infected urban clinical cohort
7. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine
8. Intracellular metabolism of the anti-herpes agent, (S)-1-[3-hydroxy-2-(phosphonyl-methoxy) propyl]cytosine (HPMPC)
9. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, a potent and selective inhibitor of human cytomegalovirus replication
10. Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS
11. Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine (HPMPC) on Simian Varicella infection in monkeys
12. Activity of (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs
13. (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl] cytosine (Cidofovir): Results of a phase I/II study of a novel antiviral nucleotide analogue
14. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: The HPMPC Peripheral Cytomegalovirus Retinitis Trial. A randomized, controlled trial
15. Intravenous cidofovir retinitis in patients with AIDS. A randomized, controlled trial
16. Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods
17. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
18. The use of nitrogen mustards in the palliative treatment of carcinoma: With particular reference to bronchogenic carcinoma
19. New visual acuity charts for clinical research
20. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS
21. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome
22. Nonparametric estimation from incomplete observations
23. A confidence interval for the median survival time
24. The robust inference for the Cox proportional hazards model
25. Test of hypotheses in an overdispersed Poisson regression and other quasi-likelihood models
26. Longitudinal data analysis using generalized linear models
27. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis
28. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis
29. Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS
30. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
31. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy
32. Discontinuing anti-CMV therapy in patients with immune reconstitution after combination antiretroviral therapy
33. MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. The Monoclonal Antibody Cytomegalovirus Retinitis Trial
34. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS
35. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial
36. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group
37. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant
38. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS: Recommendation of an International AIDS Society - USA Panel
39. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: Recommendations of an International AIDS Society - USA panel
40. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
41. AIDS and ophthalmology: A period of transition
42. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
43. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome
44. Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report